{"id":130704,"date":"2026-07-07T11:02:38","date_gmt":"2026-07-07T17:02:38","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=130704"},"modified":"2026-07-07T11:02:38","modified_gmt":"2026-07-07T17:02:38","slug":"what-is-survodutide-the-glp-1-glucagon-drug-for-obesity-and-liver-disease","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/what-is-survodutide-the-glp-1-glucagon-drug-for-obesity-and-liver-disease\/","title":{"rendered":"What Is Survodutide? The GLP-1\/Glucagon Drug for Obesity and Liver Disease"},"content":{"rendered":"

Survodutide is an investigational once-weekly injectable from Boehringer Ingelheim and Zealand Pharma, being developed for both obesity and liver disease. It’s a dual agonist that activates the GLP-1 and glucagon receptors, and in its main obesity trial it produced average weight loss of up to about 16.6% over 76 weeks. What makes survodutide stand out is its glucagon component, which appears to target liver fat directly, making it a leading candidate for treating a serious fatty liver condition called MASH. As of mid-2026, survodutide is not yet FDA approved; it’s in late-stage (phase 3) trials for both obesity and liver disease.<\/p>\n

The dual mechanism<\/h3>\n

Survodutide combines two hormone pathways with complementary roles.<\/p>\n

The GLP-1 component works like other drugs in the class, reducing appetite and increasing fullness so you eat less. This drives much of the weight loss.<\/p>\n

The glucagon component is the differentiator. Glucagon receptor activation is thought to increase energy expenditure and, importantly, prompt the liver to burn its stored fat. That liver effect is why survodutide is being studied so heavily for liver disease, not just weight.<\/p>\n

What the trial data shows<\/h3>\n

The obesity evidence comes from the SYNCHRONIZE-1 trial published in the New England Journal of Medicine in 2026<\/a>, which found that survodutide produced average weight loss of up to about 16.6% over 76 weeks compared with roughly 3% for placebo, while largely preserving muscle mass. In a companion liver-focused trial, survodutide reduced liver fat substantially, with a majority of participants with fatty liver disease reaching liver fat normalization.<\/p>\n

Here’s how the weight loss compares with approved drugs:<\/p>\n

\n\n\n\n\n\n\n\n
Medication<\/th>\nMechanism<\/th>\nApprox. weight loss<\/th>\nStandout feature<\/th>\n<\/tr>\n<\/thead>\n
Semaglutide (Wegovy)<\/td>\nGLP-1<\/td>\nAbout 15%<\/td>\nEstablished track record<\/td>\n<\/tr>\n
Tirzepatide (Zepbound)<\/td>\nGIP, GLP-1<\/td>\nAbout 20 to 22%<\/td>\nHighest approved weight loss<\/td>\n<\/tr>\n
Survodutide<\/td>\nGlucagon, GLP-1<\/td>\nUp to about 16.6%<\/td>\nDirect liver fat reduction<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

The liver disease angle<\/h3>\n

MASH (metabolic dysfunction-associated steatohepatitis) is a progressive liver disease driven by fat buildup in the liver, and it’s closely tied to obesity. It can lead to inflammation, scarring (fibrosis), and serious liver damage over time. Survodutide’s glucagon-driven reduction in liver fat is what makes it especially promising here, and it’s being tested in dedicated phase 3 liver trials that look at fibrosis, not just weight. For someone with both obesity and liver disease, a drug that addresses both could be valuable, though the trials need to finish before that’s established.<\/p>\n

Side effects<\/h3>\n

Survodutide’s side effects align with the GLP-1 class, primarily gastrointestinal effects that were mild to moderate and occurred more often during dose escalation. No unexpected safety signals outside the class have been highlighted so far, but as with any investigational drug, the picture continues to develop as larger trials report.<\/p>\n

Where it stands<\/h3>\n

Survodutide is in phase 3 development for obesity (the SYNCHRONIZE program) and for MASH with fibrosis (the LIVERAGE program), with results reading out across 2026 and into 2027. It’s not available by prescription and won’t be unless and until it completes trials and earns FDA approval.<\/p>\n

Common questions<\/h3>\n

Is survodutide available yet?<\/h4>\n

No. It’s investigational and in phase 3 trials as of 2026. It can’t be prescribed outside of a study.<\/p>\n

Is survodutide better for weight loss than Ozempic?<\/h4>\n

In trials it produced somewhat more weight loss than semaglutide, but its bigger distinction is the liver benefit. Whether it’s “better” depends on the individual and the goal.<\/p>\n

What makes survodutide different?<\/h4>\n

The glucagon component, which appears to reduce liver fat directly, sets it apart and drives its focus on liver disease alongside weight.<\/p>\n

The bottom line<\/h3>\n

Survodutide is a promising dual agonist with a distinctive liver-protective angle, but it’s still in trials and not available yet. If you’re ready to address weight now, effective approved options exist. You can see what you’re a candidate for through TrimRx’s quiz<\/a> and talk through your goals, including any liver-health concerns, with a licensed provider.<\/p>\n

This information is for educational purposes and is not medical advice. Survodutide is investigational and not FDA approved. Consult a healthcare provider before starting any medication or for concerns about liver health. Individual results may vary.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Survodutide is an investigational once-weekly injectable from Boehringer Ingelheim and Zealand Pharma, being developed for both obesity and liver disease. It’s a dual agonist…<\/p>\n","protected":false},"author":7,"featured_media":106597,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[],"class_list":["post-130704","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=130704"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130704\/revisions"}],"predecessor-version":[{"id":130705,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130704\/revisions\/130705"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/106597"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=130704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=130704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=130704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}